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For more than 80 years, insecticides have
been one of the primary means of controlling
insect-borne diseases. Recently, however, the
control of insect pests and vectors of disease has
become increasingly difficult for various reasons,
including the emergence of insecticide resistance,
changes in the environment, and reduction in
public health interventions due to social and
economic problems in countries where insect-
borne diseases are endemic. According to the
World Health Organization (WHO), approxi-
mately 125 arthropod species are resistant to at
least one, and often two or more, insecticides (1).
In many parts of the world where insect-borne
diseases cause illness and death, insecticides are
available; however, sustaining insecticide vector
control long term can be extremely costly and
may be unachievable.
Alternative Approaches to Controlling
Disease Transmission by Arthropods
Concerns related to the use of insecticides for
vector control have led to alternative approaches
for reducing disease transmission by arthropods.
One approach focuses on the use of transgenic
methods, i.e., the insertion and expression of a
gene derived from one organism in a second,
heterologous organism. Major components of the
transformation system include the identification
of 1) potential DNA vectors (transposable
elements or viral-transducing agents) for
genome integration (2-8); 2) selectable pheno-
typic marker genes, such as eye color mutants or
various enzymes (e.g., ß-galactosidase, neomycin
phosophotransferase, or organophosphate-de-
grading enzyme), as indicators of stable germ
line transformation (9-11); and 3) specific
refractory genes that express the desired
phenotype (i.e., a factor that would inhibit
transmission of the pathogen) (12-14). Addi-
tional studies have focused on the identification
of regulatory sequences (e.g., stage-specific,
tissue-specific, and constitutive promoters [15-
20]), vector population genetics (21-23), and the
development of mathematical models that can be
used for predicting the behavior of genes once
they are introduced into wild populations (24,25).
The accomplishments and future prospects of
efforts to produce transgenic arthropods have been
discussed extensively (26-31).
Another approach for reducing disease
transmission by arthropods is to genetically
modify symbiotic bacteria of arthropod vectors to
prevent the arthropods from transmitting
human pathogens. With this approach, the
arthropod is not transformed, but the symbiotic
bacteria that it harbors are (32). Such arthropods
are called paratransgenic. This approach is
guided by the following basic concepts: 1) many
arthropods (especially those that throughout
their entire developmental cycle feed on
restricted food sources such as blood, cellulose,
phloem, stored grains) harbor bacterial sym-
bionts; 2) in some cases, these symbionts can be
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cultured and genetically transformed to express
a gene whose product kills a pathogen that the
arthropod transmits; 3) normal arthropod
symbionts can be replaced with genetically
modified symbionts, resulting in a population of
arthropod vectors that can no longer transmit
disease. While not applicable to all groups of
arthropods, this approach has worked in three
species of Chagas disease vectors and holds
promise in a number of other arthropods.
Bacterial Symbionts and Control of
American Trypanosomiasis
American trypanosomiasis (Chagas disease)
is a parasitic illness that affects 16 to 18 million
people in regions of South and Central America,
according to current WHO estimates. Neither a
cure for chronic Chagas disease nor a vaccine for
preventing infection is available. The etiologic
agent, the flagellate protozoon Trypanosoma
cruzi, is transmitted by blood-sucking triatomine
bugs, which become infected while feeding on an
infected host. Transmission to humans occurs as
the insect feeds when the engorged triatomine
bug, while feeding, deposits on the skin a fecal
droplet that contains infective trypanosomes,
which then get rubbed either into the bite lesion
or a mucous membrane (Figure 1).
Rhodnius prolixus is the chief vector of
Chagas disease in certain regions of Central
America and northern South America.
Rhodococcus rhodnii, a soil-associated
nocardiform actinomycete, residing extracellu-
larly in the gut lumen of R. prolixus in close
proximity to T. cruzi (33), is transmitted effectively
from adult triatomid bugs to their progeny
through coprophagy (ingestion of fecal mate-
rial from other bugs). The vital role of R.
rhodnii in the growth and development of R.
prolixus has been demonstrated repeatedly
under laboratory conditions (34-36). Aposymbiotic
nymphs of R. prolixus (insects that have been
cured of symbionts) do not reach the sexually
mature adult stage; most deaths occur after the
second developmental molt. Introduction of the
bacteria to first or second instar nymphs permits
normal growth and maturation.
Scientists have exploited this symbiotic
association to introduce and express a series of
foreign gene constructs in R. prolixus (37,38).
DNA shuttle plasmids capable of replication in
both Escherichia coli and in R. rhodnii have
been constructed and used to genetically
modify  R. rhodnii (Figure 2). The genetically
altered symbionts can then be introduced into
aposymbiotic first instar nymphs of R. prolixus,
where, like unmodified microorganisms, they
allow normal growth and reproduction of the
insect while expressing specific gene products
of interest.
In our laboratory, a selectable genetic
marker coding for resistance to the antibiotic
thiostrepton was expressed by transgenic
symbionts within the gut of insects colonized
experimentally (37). The insects could be fed on
blood that contained thiostrepton, and the
bacteria survived and persisted throughout the
insects development to adulthood. Furthermore,
we showed that when thiostrepton was omitted
from the blood, the symbionts maintained
Figure 1. A triatomine bug vector of Chagas disease in
the process of feeding. The fecal droplet contains
infective trypanosomes and bacterial symbionts.
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resistance to the antibiotic, which indicates that
the plasmid was stable in its bacterial host. By
sterilizing the surface of the eggs with a topical
iodine solution and colonizing the resulting
aposymbiotic (sterile) insects with genetically
modified symbionts (delivered to the insects
orally), we developed a line of paratransgenic
arthropods in which individual insects were
refractory to infection with T. cruzi (38).
Refractoriness was conferred after the antimi-
crobial peptide L-Cecropin A was expressed and
secreted. The gene for this peptide was contained
in a shuttle plasmid expression vector used to
transform  R. rhodnii, which subsequently
expressed and secreted the gene product within
the gut of experimentally colonized insects (38).
Cecropin A, a 38amino acid peptide, belongs to a
family of small channel-forming peptides with
potent antimicrobial activity; these peptides
insert into biologic membranes, forming chan-
nels that ultimately lead to cell lysis and death
(39-41). This family of peptides has been isolated
from several insect and vertebrate tissues, which
they defend against bacterial pathogens (41).
Cecropin A has strong lytic activity against T.
cruzi but negligible deleterious effects on R.
rhodnii or gut tissues of R. prolixus. Laboratory
colonies of R. prolixus that carried genetically
altered  R. rhodnii transformed to express
mature Cecropin A were completely refractory to
infection with T. cruzi strain DM28 in
approximately 70% of the insects. In the
remaining insects, numbers of T. cruzi were
reduced to less than 1% of the numbers seen in
control R. prolixus, which carried untransformed
R. rhodnii.
These studies demonstrate that symbiotic
bacteria of disease-transmitting triatomine bugs
can be genetically modified to express biologi-
cally active molecules and then can be
reintroduced into the host insect, expressing the
desired phenotype (Figure 3). The genetically
altered R. rhodnii allowed normal development
and sexual maturation of the host insect.
Delivery Mechanisms/Field Applications
For the bacterial symbiont approach to be
used in a field intervention program, a
mechanism must be developed for spreading the
genetically altered bacteria through an insect
population. The delivery system must allow
dispersal of recombinant genetic material
without adverse environmental effects. Using
bacteria that have specialized symbiotic associa-
tions with specific insect hosts to spread
transgenes greatly reduces the chance of
unwanted gene spread; the natural insect-
symbiont association can be used for this
purpose. In R. prolixus, early instar nymphs
acquire the symbiont R. rhodnii by coprophagy.
When they first emerge, instar nymphs are
transiently aposymbiotic; they pick up the
required bacteria by probing the eggshell or fecal
droplets of other bugs (Figure 1). Scientists have
observed that triatomine bugs actively probe
small dots of black ink on paper, apparently
because they resemble the black fecal droplets
shed by triatomine bugs after digestion of the
bloodmeal. When live bacterial cultures and a
small amount of India ink are added to an inert
Figure 2. Shuttle plasmid for genetic transformation
of Rhodococcus rhodnii.
Figure 3. Symbionts can be genetically altered and
used to replace native symbionts, resulting in insects
that can no longer transmit disease. (Illustration
courtesy of Mark Q. Benedict).584 Emerging Infectious Diseases Vol. 4, No. 4, OctoberDecember 1998
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carrier, a formulation of the genetically modified
bacteria is produced that resembles bug feces
and can be ingested by immature insects; in this
way, modified bacteria can be established
uniformly and effectively in laboratory colonies
of  R. prolixus (37,38). Studies to test this
approach in the laboratory use a design that
simulates a field application. Wooden frames
composed of housing materials common in the
rural tropics (primarily mud and thatch) are
treated with the bacterial formulation. Field-
collected  R. prolixus are added to these frames,
which are then enclosed in large plexiglass
containers. The progeny of the field-collected
insects are examined for colonization with the
modified symbiont, ability of the symbiont to
compete with native symbionts established in
the field-collected specimens, and expression of
the desired transmission phenotype.
A possible strategy for using vector-symbiont
intervention for the control of Chagas disease
transmission would require that in disease-
endemic areas, individual houses likely to
become infested with triatomines be treated with
the bacterial formulation, either when they are
new and uncolonized or after insecticide
treatment that kills any resident insects,
especially in corners and cracks where they are
most likely to hide. In homes treated with the
bacterial formulation, which likely contain wild-
type symbionts, the genetically modified sym-
bionts could be given a competitive advantage of
being applied in greater concentrations than the
native symbionts. As triatomine bugs from
adjacent untreated areas reinfest the house,
they would lay their eggs, which would hatch
within days. The digestive tract of the new
immature bugs would be colonized through
coprophagy with genetically altered symbionts,
which would keep them from subsequently
becoming infected with the Chagas disease
trypanosome. These progeny would then amplify
and disperse the altered symbionts through
natural coprophagic routes. Since triatomine
bugs involved in domiciliary transmission must
invade and become established in the homes,
peridomestic or sylvatic habitats would not need
to be treated to affect domestic transmission.
Because of the labor and expense involved in
repeated insecticide treatment, reinfestation is a
potential major obstacle in Chagas disease
control. Vector-symbiont intervention could play
an important role in an integrated control
approach that used a combination of insecticidal
and molecular genetic interventions.
Bacterial Symbionts in Tsetse
Bacterial symbionts have also been evalu-
ated in other insect disease vectors. The tsetse
vectors of African sleeping sickness (trypanoso-
miasis) harbor as many as three distinct
populations of bacterial flora (33,42-45). Like
triatomine bugs, tsetse are obligate bloodfeeders,
and at least one population of bacteria (found in
uterine secretory cells) is presumed to be
nutritional mutualist symbionts. The primary,
or P-symbionts, are highly specialized intracellu-
lar bacteria apparently essential for the flies
survival (33,45). These bacteria have not been
cultured or transformed. The secondary, or S-
symbionts, comprise another population of
gram-negative bacteria found in various tissues
of tsetse, including the salivary glands, where
they reside in large numbers, especially in older
flies (S. Aksoy, pers. comm.). S-symbionts can be
isolated from hemolymph and cultivated in vitro,
where they have been shown to grow both intra-
and extracellularly (Figure 4) (46-48). A potential
transformation system has been developed for
these bacteria with the recombinant plasmid
pSUP204 (47). This DNA vector contains the
broad host range replicon oriV, derived from a
Pseudomonas aeruginosa plasmid, RSF1010,
and ligated into the E. coli cloning vector pBR325
(49,50). Recent studies indicate that genetically
transformed tsetse S-symbionts can be microin-
jected into recipient flies and express a reporter
Figure 4. The tsetse secondary symbiont GP01
growing intracellularly and extracellularly in
culture.585 Vol. 4, No. 4, OctoberDecember 1998 Emerging Infectious Diseases
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gene (S. Aksoy, pers. comm.). This area of
research will likely yield new approaches for
controlling tsetse transmission of trypanosomes.
Intracellular Insect Reproductive System
Agents—Wolbachia
Obligate intracellular bacteria found in
many species of arthropods (51,52), the
Wolbachia are maternally transmitted from
parent to offspring and are often involved in a
variety of reproductive anomalies, such as
cytoplasmic incompatibility (reproductive in-
compatibility due to maternal, nongenetic
factors), sex ratio determination and distortions,
and parthenogenesis (53-56). Although ex-
tremely fastidious, these microbes could be used
in the transgenic alteration of arthropod vectors
in two ways (32): 1) direct transformation and
subsequent expression of a gene product by the
Wolbachia in the arthropod, and 2) use of
Wolbachia-induced cytoplasmic incompatibility
to drive a second, maternally inherited factor
into a population of vectors. The first approach
entails the use of either episomal plasmids or
DNA integration vectors for transformation of
the Wolbachia. Although theoretically possible,
such a transformation system (i.e., a suitable
DNA vector and methods for introducing the
DNA and selecting for transformants) does not
now exist. Recent successful genetic transforma-
tion of rickettsial agents, however, suggests that
this limitation may soon be overcome (57).
Since Wolbachia are frequently observed in
reproductive tissues of arthropods (Figure 5),
one potential approach that they might be used
to disrupt transmission of a pathogen is
suggested by studies performed using a viral
transduction system in the mosquito Aedes
aegypti (14).  In these experiments, antisense
DNA sequences corresponding to a membrane
protein of the dengue type 2 virus were
expressed somatically by using a recombinant
Sindbis virus vector.  Mosquitoes that were
coinfected with the two viruses were shown not
to be able to transmit dengue virus.  Similar work
has been done with Aedes triseriatus mosquitoes,
which are potential vectors of the LaCrosse virus
(58).  These types of experiments could be done
by using genetically modified Wolbachia, with
the goal of blocking transovarial transmission of
an arboviral agent, such as La Crosse
encephalitis virus or Rift Valley Fever virus,
which is dependent on vertical transmission
from the adult mosquito to its progeny for
maintenance of the virus in nature.  Genetically
transformed  Wolbachia  could be utilized in a
manner similar to that of viral transducing
agents to express antisense DNA sequences that
interfere with replication of transovarially
transmitted virus pathogen.
The disruption of transovarial transmission
is an application that could potentially be
adapted for use in a number of species of
mosquitoes, ticks, and mites in which transovarial
transmission of pathogens is important.  Very
recent studies report the distribution of
Wolbachia throughout somatic and germ-line
tissues in various insects.  These observations
suggest that potential transmission-blocking
applications using genetically modified Wolbachia
would not be limited simply to transovarially
transmitted agents but potentially applicable to
microbial pathogens that reside and/or replicate
Figure 5. Wolbachia-like organisms in insect
reproductive tissues.586 Emerging Infectious Diseases Vol. 4, No. 4, OctoberDecember 1998
Synopses
in other insect tissues as well, such as the
hemolymph or salivary glands (59).
Alternatively,  Wolbachia could be used to
render a population of arthropod disease vectors
incapable of transmitting a disease agent:
Wolbachia-mediated cytoplasmic incompatibil-
ity could spread a second maternally inherited
gene into the vector population. In its simplest
form (Figure 6), cytoplasmic incompatibility
results when a Wolbachia-negative female mates
with a Wolbachia-positive male; no offspring are
produced from such an incompatible cross. Since
the reciprocal cross between an infected female
and an uninfected male results in Wolbachia-
infected progeny, the net effect in matings
between the two strains, other things being
equal, is that Wolbachia-infected progeny will be
more prevalent than Wolbachia-free progeny.
This phenomenon has been observed in natural
populations of Wolbachia-infected and -uninfected
Drosophila simulans in California, demonstrat-
ing the rapid spread of Wolbachia and the
corresponding cytoplasmic incompatibility phe-
notype across broad geographic regions (61).
How this phenomenon might be utilized has been
discussed in great detail (32,60).
As Wolbachia spread through the population
by cytoplasmic incompatibility, other maternally
inherited organisms (or organelles) in the
Wolbachia-infected strains are transmitted.
Cage studies, using mosquitoes with different
mitochondrial haplotypes, have found that
haplotype frequencies changed so quickly that
within two generations, one haplotype was
completely replaced by the other as a result of
Wolbachia-driven cytoplasmic incompatibility (62).
In an actual scheme for genetic modification
of a vector population, the gene blocking
pathogen transmission could be carried by a
second, nonpathogenic species of bacteria, such
as the tsetse S-symbiont (32,63) or a rickettsialike
commensal that is maternally inherited (64), or
even possibly an organelle such the mitochon-
drion. The transformed agent could be intro-
duced into a Wolbachia-infected laboratory
colony, and the females could be released. Over
time, because of the driving mechanism of
cytoplasmic incompatibility, a gene product
critical for transmission of an arthropod-borne
disease agent could be blocked by a second
product expressed and secreted by the geneti-
cally transformed, maternally inherited micro-
organism, resulting in the modification of the
vector populations capacity to transmit the
disease agent.
Limitations
The application of these methods is limited
primarily by the occurrence of suitable
microorganisms in specific arthropod vectors. In
general, many arthropods (e.g., ticks, mites,
triatomine bugs, bed bugs, lice, some species of
fleas, and tsetse) that feed on single food sources
throughout their entire developmental cycle
contain microbial symbionts that produce
nutritional supplements lacking in the restricted
diet (so called nutritional mutualists) (33,65,66).
Mosquitoes and many other dipterans, however,
do not fall into this category because they do not
feed on blood strictly as a source of nutrition for
basal metabolism; rather, the females alone feed
on blood, which is used directly to produce
progeny. Although other symbionts may be
present in mosquitoes, nutritional mutualists
are altogether lacking.
Reported from numerous and diverse species
of arthropods (51), Wolbachia may occur
naturally in more than 15% of all insect species
(67).  Wolbachia have been transferred in the
laboratory from one arthropod species to
another, successfully conferring the cytoplasmic
incompatibility phenotype to the recipient
species (68,69). Other passenger microorgan-
isms, such as tsetse S-symbionts (33,42) and
Rickettsia-like organisms (70,71), are common in
arthropods, and although the nature of their
symbiotic relationship with the arthropod host is
often unclear, their consistent association
Figure 6. Wolbachia-mediated cytoplasmic incom-
patibility.587 Vol. 4, No. 4, OctoberDecember 1998 Emerging Infectious Diseases
Synopses
suggests their potential as vehicles for express-
ing a transgene in the arthropod.
Other limitations to the use of arthropod
bacteria include the development of appropriate
transformation methods and reagents. Because
many nonpathogenic microorganisms in
arthropods have been poorly studied and
characterized, accurate identification of the
agent is a prerequisite to genetic transformation
studies. These microorganisms can be character-
ized either through traditional bacteriologic
characterization or by a polymerase chain
reactionbased approach that uses common
eubacterial primers to amplify the 16S rRNA
locus that can be sequenced and used for
identifying the microbe (72,73). DNA vectors and
transformation methods have been developed for
diverse groups of both gram-positive and -
negative microorganisms; these tools and
approaches can often be adapted for use with a
bacterial symbiont or passenger. We have
efficiently transformed several species of coryne-
form bacteria, common agents of various
triatomine bugs that transmit Chagas disease, by
using transformation vectors and regulatory
sequences developed for use in Mycobacterium spp.
Release of Paratransgenic Insects:
Regulations and Safety
In addition to questions regarding science
and efficacy, numerous safety and regulatory
concerns pertaining to laboratory and field
research with genetically modified arthropod
vectors of human disease must be addressed.
These concerns include potential environmental
and ecologic hazards associated with release;
potential public health risks; and overall public
perception, which can determine the future of
entire programs (74,75).
In the United States, federal guidelines and
regulations address a broad range of issues
pertaining to research, transport, and release of
microorganisms, plants, and insects. The U.S.
Department of Agriculture Animal and Plant
Inspection Service (APHIS) regulates the release
of transgenic arthropods of agricultural impor-
tance. None of these guidelines or regulations,
however, directly address genetically modified
arthropod vectors of human disease agents.
Nevertheless, the work that has been done and
the policy that is in place set a precedent.
The basic principles of containment regard-
ing research with transgenic and paratransgenic
insect disease vectors are similar to those
regarding human pathogens and biologic
insecticide agents (insects and microorganisms).
Guidelines that discuss established standards
for work with human disease agents, typically
classified as biosafety level (BSL)-2, BSL-3, or
BSL-4, on the basis of the assessment of
virulence and transmissibility have been
published (76), and a permitting process
oversees the import and transport of these
agents into and throughout the United States.
The Environmental Protection Agency (EPA)
and USDA-APHIS share oversight with regard
to the development and use of biologic
insecticides (77). USDA-APHIS also regulates
the use of insects and arthropods that are
predators of insect pests. The containment
procedures and facilities associated with the use
of these organisms in new geographic regions in
the United States might be adapted as the
minimum standards for work with transgenic
arthropods (75).
With respect to regulation of the release of
transgenic arthropods of agricultural impor-
tance and risk assessment, USDA-APHIS has
formed an interagency virtual committee
charged with the responsibility of evaluating
proposals to release transgenic arthropods that
could affect plants and animals (excluding
humans); efforts are under way to form an
interagency committee with the authority to
regulate the release of arthropods that could
affect humans. Information on the program that
APHIS has assembled, including details regard-
ing permits and current applications that have
been submitted under several plant pest statutes,
can be accessed at http://www.aphis.usda.gov/
biotech/arthropod/; risk assessment information
is also available at this site.
Assessment of the environmental risks of
releasing transgenic and paratransgenic
arthropods shares principles with environmen-
tal impact analysis of biologic insecticides (78).
The same arguments used to promote the
potential benefits of recombinant organisms are
equally effectively used to argue the potential
hazards (79). To assess risk, Hoy (74) addresses
four basic concerns: 1) the attributes of the
unmodified organism; 2) attributes of the
genetic alteration, i.e., only of the gene
transferred; 3) phenotype of the modified
organism compared with the unmodified
organism; and 4) attributes of the accessible588 Emerging Infectious Diseases Vol. 4, No. 4, OctoberDecember 1998
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environment. These concerns can guide formula-
tion of research plans to assess environmental
risks associated with the release of transgenic
arthropods.
Transgenic and paratransgenic research
with arthropods raises several public health
concerns. Because the arthropods may transmit
human disease agents, ethical issues must be
considered. For example, consider that a
transgenic or paratransgenic insect is released
under the assumption that its ability to transmit
disease has been demonstrated to be signifi-
cantly decreased or eliminated, as determined by
laboratory studies in carefully defined condi-
tions.  Then suppose that when pilot field studies
are conducted, for some reason, it is shown that
under true field conditions the ability to transmit
disease is not reduced as much as had been
anticipated on the basis of the controlled
laboratory studies. The result is that the human
population present where the release takes place
could actually be at increased risk for disease due
to the release of large numbers of competent or
partially competent vectors.  The assessment of
this type of risk is extremely important, as is the
related human subjects issue of informed
consent and how it would be obtained in a study
where the population that is potentially at risk
cannot be accurately determined.
Public perception, frequently not considered
until a potential product is ready for field testing,
is extremely important (e.g., public response to
genetic control studies in India in the 1970s,
including the release of sterile mosquitoes [80]
and to the ongoing controversy surrounding the
labeling of foods that are, or contain, the
products of genetic engineering in agriculture
[81-83]). The most effective biotechnology
programs are those in which the public is
informed and brought into discussions at the
earliest possible time (75,84).
The efficacy of a biologic agent to prevent or
reduce the impact of a disease is of paramount
importance, yet most of this information can be
obtained definitively only after the method has
been tested on a large scale and under different
environmental conditions. On the other hand,
information on safety, as well as on the behavior
of the agent in the field, is required before we
know how well it works and what other effects it
has on the environment. Thus, the scientist
developing a new agent must make an honest,
imaginative leap into the future and try to
predict any possible dangerous consequences
the responsibility for risk assessment must be
shouldered by the scientist, together with the
appropriate regulatory agencies. Because the
safety questions are numerous, those of the
greatest potential significance, both in the short
term and in the long term, should be examined
first. The risks associated with the intervention
must be assessed against the risk for disease, the
risk to health and the environment from
pesticides, and the risk of doing nothing.
Conclusions
Decreasing effectiveness of controlling dis-
eases transmitted by arthropods has led to
evaluation of new control strategies, including
the use of transgenic methods. A strategy that
relies on producing paratransgenic arthropods
has been applied with initial success to the
triatomine bugs that transmit Chagas disease,
resulting in vector strains incapable of being
infected with the pathogenic agent T. cruzi. This
approach may also prove feasible for a number of
other vector-borne diseases, using either
nutritional symbionts of arthropods that feed
exclusively on blood, Wolbachia that have been
successfully transferred between species in the
laboratory, or other microbial passengers
consistently associated with their arthropod
host. As the tools and methods that allow broader
applications of this approach are developed,
and actual products arrive at the point of field
testing, permitting and regulation will be
required.
The regulatory process must begin with the
individual investigators, who must thoroughly
evaluate the product being developed and work
with regulatory agencies and others to ensure
that if and when genetically modified organisms
are used for the control of insect borne diseases,
they will be both safe and efficacious.
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